Japan Glp-1 Receptor Agonist Market Size & Outlook
Japan glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Japan glp-1 receptor agonist market highlights
- The Japan glp-1 receptor agonist market generated a revenue of USD 360.6 million in 2023 and is expected to reach USD 1,238.3 million by 2030.
- The Japan market is expected to grow at a CAGR of 19.3% from 2024 to 2030.
- In terms of segment, trulicity was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 360.6 million |
| Market revenue in 2030 | USD 1,238.3 million |
| Growth rate | 19.3% (CAGR from 2023 to 2030) |
| Largest segment | Trulicity |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Mounjaro (tirzepatide), Rybelsus (oral semaglutide), Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Japan accounted for 1.0% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 578.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Trulicity was the largest segment with a revenue share of 32.61% in 2023. Horizon Databook has segmented the Japan glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, mounjaro (tirzepatide), rybelsus (oral semaglutide), saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most technologically advanced countries in the Asia Pacific. Its GLP-1 receptor agonist market is expected to grow rapidly over the forecast period due to high government spending to reduce the disease burden.
Multiple initiatives, such as government grants to various research institutes and companies, can help develop practical solutions for the high burden of various lifethreatening diseases in the country. Moreover, the rising focus of key players operating in the market on developing technologically advanced solutions to discover & develop novel therapeutics is further propelling market growth.
Moreover, various organic and inorganic initiatives by leading participants are driving the market in Japan. The local presence of manufacturers in the region, coupled with their continuous R&D efforts to introduce innovative solutions, is contributing to market growth.
Reasons to subscribe to Japan glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Japan glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Japan glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Japan glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Japan GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
